Proton beam reirradiation for locally recurrent rectal cancer patients with prior pelvic irradiation.

Abstract

The aim of the present study was to report the feasibility of proton beam reirradiation for patients with locally recurrent rectal cancer (LRRC) with prior pelvic irradiation. The study population included patients who were treated with proton beam therapy (PBT) for LRRC between 2008 and December 2019 in our institution. Those who had a history of distant metastases of LRRC, with or without treatment, before reirradiation, were excluded. Overall survival (OS), progression-free survival (PFS) and local control (LC) were estimated using the Kaplan-Meier method. Ten patients were included in the present study. The median follow-up period was 28.7months, and the median total dose of prior radiotherapy (RT) was 50Gy (range, 30Gy-74.8Gy). The median time from prior RT to reirradiation was 31.5months (range, 8.1-96.6months), and the median reirradiation dose was 72Gy (relative biological effectiveness) (range, 56-77Gy). The 1-year/2-year OS, PFS and LC rates were 100%/60.0%, 20.0%/10.0% and 70.0%/58.3%, respectively, with a median survival time of 26.0months. Seven patients developed a Grade 1 acute radiation dermatitis, and no Grade≥2 acute toxicity was recorded. Grade≥3 late toxicity was recorded in only one patient, who had developed a colostomy due to radiation-related intestinal bleeding. Reirradiation using PBT for LRRC patients who had previously undergone pelvic irradiation was feasible. However, the indications for PBT reirradiation for LRRC patients need to be considered carefully due to the risk of severe late GI toxicity.